Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
J Intern Med ; 268(1): 66-74, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20210841

ABSTRACT

OBJECTIVES: To determine sex/gender differences in the distribution of risk factors according to age and identify factors associated with the presence of severe coronary artery disease (CAD). DESIGN: We analysed 23,771 consecutive patients referred for coronary angiography from 2000 to 2006. SUBJECTS: Patients did not have previously diagnosed CAD and were referred for first diagnostic angiography. OUTCOME MEASURES: Patients were classified according to angiographic disease severity. Severe CAD was defined as left main stenosis > or = 50%, three-vessel disease with > or = 70% stenosis or two-vessel disease including proximal left anterior descending stenosis of > or = 70%. Univariate and multivariate logistic regression was used to assess the association between risk factors and angina symptoms with severe CAD. RESULTS: Women were less likely to have severe CAD (22.3% vs. 36.5%) compared with men. Women were also significantly older (69.8 +/- 10.6 vs. 66.3 +/- 10.7 years), had higher rates of diabetes (35.0% vs. 26.6%), hypertension (74.8% vs. 63.3%) and Canadian Cardiovascular Society (CCS) class IV angina symptoms (56.7% vs. 47.8%). Men were more likely to be smokers (56.9% vs. 37.9%). Factors independently associated with severe CAD included age (OR = 1.05; 95% CI 1.05-1.05, P < 0.01), male sex (OR = 2.43; CI 2.26-2.62, P < 0.01), diabetes (OR = 2.00; CI 1.86-2.18, P < 0.01), hyperlipidaemia (OR = 1.50; CI 1.39-1.61, P < 0.01), smoking (OR = 1.10; CI 1.03-1.18, P = 0.06) and CCS class IV symptoms (OR = 1.43; CI 1.34-1.53, P < 0.01). CCS Class IV angina was a stronger predictor of severe CAD amongst women compared with men (women OR = 1.82; CI 1.61-2.04 vs. men OR = 1.28; CI 1.18-1.39, P < 0.01). CONCLUSIONS: Women referred for first diagnostic angiography have lower rates of severe CAD compared with men across all ages. Whilst conventional risk factors, age, sex, diabetes, smoking and hyperlipidaemia are primary determinants of CAD amongst women and men, CCS Class IV angina is more likely to be associated with severe CAD in women than men.


Subject(s)
Coronary Disease/etiology , Age Factors , Aged , Angina Pectoris/epidemiology , Coronary Angiography , Coronary Disease/diagnostic imaging , Coronary Disease/epidemiology , Coronary Disease/pathology , Diabetic Angiopathies/epidemiology , Epidemiologic Methods , Female , Humans , Hyperlipidemias/complications , Hyperlipidemias/epidemiology , Hypertension/complications , Hypertension/epidemiology , Male , Middle Aged , Ontario/epidemiology , Sex Factors , Smoking/adverse effects , Smoking/epidemiology
2.
J Am Coll Cardiol ; 38(5): 1440-9, 2001 Nov 01.
Article in English | MEDLINE | ID: mdl-11691521

ABSTRACT

OBJECTIVES: We sought to compare survival after coronary artery bypass graft (CABG) and percutaneous transluminal coronary angioplasty (PTCA) in high-risk anatomic subsets. BACKGROUND: Compared with medical therapy, CABG decreases mortality in patients with three-vessel disease and two-vessel disease involving the proximal left anterior descending artery (LAD), particularly if left ventricular (LV) dysfunction is present. How survival after PTCA and CABG compares in these high-risk anatomic subsets is unknown. METHODS: In the Bypass Angioplasty Revascularization Investigation (BARI), 1,829 patients with multivessel disease were randomized to an initial strategy of PTCA or CABG between 1988 and 1991. Stents and IIb/IIIa inhibitors were not utilized. Since patients in BARI with diabetes mellitus had greater survival with CABG, separate analyses of patients without diabetes were performed. RESULTS: Seven-year survival among patients with three-vessel disease undergoing PTCA and CABG (n = 754) was 79% versus 84% (p = 0.06), respectively, and 85% versus 87% (p = 0.36) when only non-diabetics (n = 592) were analyzed. In patients with three-vessel disease and reduced LV function (ejection fraction <50%), seven-year survival was 70% versus 74% (p = 0.6) in all PTCA and CABG patients (n = 176), and 82% versus 73% (p = 0.29) among non-diabetic patients (n = 124). Seven-year survival was 87% versus 84% (p = 0.9) in all PTCA and CABG patients (including diabetics) with two-vessel disease involving the proximal LAD (n = 352), and 78% versus 71% (p = 0.7) in patients with two-vessel disease involving the proximal LAD with reduced LV function (n = 72). CONCLUSION: In high-risk anatomic subsets in which survival is prolonged by CABG versus medical therapy, revascularization by PTCA and CABG yielded equivalent survival over seven years.


Subject(s)
Angioplasty, Balloon, Coronary/standards , Coronary Artery Bypass/standards , Coronary Disease/mortality , Coronary Disease/therapy , Aged , Coronary Angiography , Coronary Disease/complications , Coronary Disease/diagnosis , Coronary Disease/physiopathology , Female , Follow-Up Studies , Humans , Male , Middle Aged , Multivariate Analysis , Patient Selection , Proportional Hazards Models , Registries , Regression Analysis , Risk Factors , Severity of Illness Index , Stroke Volume , Survival Analysis , Time Factors , Treatment Outcome , Ventricular Dysfunction, Left/etiology
3.
Am Heart J ; 142(3): 452-9, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11526358

ABSTRACT

BACKGROUND: The outcome of patients with previous coronary artery bypass grafting (CABG) undergoing primary percutaneous coronary intervention (PCI) for the treatment of acute myocardial infarction (AMI) is unclear. We sought to assess the outcome of patients with prior CABG undergoing primary PCI for the treatment of AMI. METHODS AND RESULTS: Between 1991 and 1997, 1072 patients with AMI underwent primary PCI without antecedent thrombolytic therapy at the Mayo Clinic. There were 128 patients with previous CABG and 944 without previous CABG. Patients with previous CABG were further subdivided according to the treated vessel: native vessels (n = 65) and bypass graft (n = 63). Clinical and angiographic characteristics and 30-day and 1-year outcomes were evaluated. Patients with previous CABG were significantly older and had a higher incidence of diabetes, hypertension, and hypercholesterolemia. They had a lower left ventricular ejection fraction and were also more likely to have congestive heart failure. After 1 year of follow-up, adverse cardiac events (death, MI, CABG, or repeat PCI) were significantly greater in patients with prior CABG (49.2% vs 35.9%, P =.04). With use of multivariate logistic regression analysis to adjust for differences in baseline characteristics, the treatment of vein graft was independently associated with adverse cardiac events (relative risk 1.48 [95% confidence interval 1.07-2.03], P =.02), but a history of prior CABG itself was not (relative risk 1.22 [95% confidence interval 0.96-1.56], P =.11). CONCLUSIONS: Primary PCI for AMI in patients with previous CABG is associated with higher adverse events largely attributable to adverse baseline clinical characteristics and the treatment of a vein graft.


Subject(s)
Angioplasty, Balloon, Coronary , Coronary Artery Bypass , Myocardial Infarction/surgery , Aged , Angina Pectoris , Coronary Angiography , Female , Humans , Male , Middle Aged , Myocardial Infarction/mortality , Myocardial Infarction/pathology , Postoperative Complications , Retrospective Studies , Risk Factors , Thrombolytic Therapy , Treatment Outcome
4.
Am J Cardiol ; 87(4): 439-42, A4, 2001 Feb 15.
Article in English | MEDLINE | ID: mdl-11179529

ABSTRACT

Among 214 patients treated with abciximab within 24 hours of full-dose thrombolytic therapy, major bleeding occurred in 50 patients (23%; 95% confidence interval [CI] 18% to 30%) and intracranial hemorrhage occurred in 3 patients (1.4%; 95% CI 0.3% to 4%). The independent multivariate predictors of major bleeding were age (odds ratio [OR] 1.53/10 years, 95% CI 1.05 to 2.21, p = 0.03), time from thrombolytic to abciximab (OR 0.91/hour, 95% CI 0.83 to 0.99, p = 0.03), and intra-aortic balloon pump insertion (OR 4.42, 95% CI 2.00 to 9.72, p = 0.0002).


Subject(s)
Antibodies, Monoclonal/adverse effects , Hemorrhage/chemically induced , Immunoglobulin Fab Fragments/adverse effects , Platelet Aggregation Inhibitors/adverse effects , Abciximab , Aged , Angioplasty , Antibodies, Monoclonal/therapeutic use , Female , Fibrinolytic Agents/therapeutic use , Humans , Immunoglobulin Fab Fragments/therapeutic use , Logistic Models , Male , Middle Aged , Myocardial Infarction/complications , Myocardial Infarction/surgery , Myocardial Ischemia/etiology , Myocardial Ischemia/prevention & control , Platelet Aggregation Inhibitors/therapeutic use , Recombinant Proteins/therapeutic use , Risk Factors , Thrombolytic Therapy , Tissue Plasminogen Activator/therapeutic use , Treatment Failure
5.
Am J Cardiol ; 86(10): 1063-8, 2000 Nov 15.
Article in English | MEDLINE | ID: mdl-11074200

ABSTRACT

Percutaneous coronary intervention (PCI) in patients with diabetes mellitus (DM) is associated with higher rates of adverse cardiac events. Recent data suggest that adverse events are reduced in DM after PCI using stents with abciximab. We performed a retrospective analysis of a prospective PCI registry for all patients with DM who underwent stent placement at the Mayo Clinic from 1995 to 1997 (n = 570), and divided them into 2 groups based on whether abciximab was administered. Characterization and comparison of the clinical and angiographic variables, procedural outcomes, and short- and long-term event rates between groups was performed. The baseline clinical characteristics of the groups were similar, but patients treated with abciximab were more likely to be men with a lower left ventricular ejection fraction. Patients treated with abciximab had more multivessel intervention, saphenous vein graft intervention, and thrombus before intervention. The 30-day mortality rate (0.6% vs 3.0%, p = 0.03) and repeat PCI (0% vs 1.1%, p = 0.03) was lower in patients treated with abciximab. The 30-day rates of bypass surgery, myocardial infarction (MI), and a composite of death, MI, and revascularization were similar. The 1-year event rates did not differ significantly between patients taking and not taking abciximab for the end points of death (8.9% vs 8.8%, p = 0.97), MI (13.3% vs 11.4%, p = 0.57), bypass surgery (10.3% vs 6.2%, p = 0.20), repeat PCI (14.7% vs 15.9%, p = 0.76), and a composite of death, MI, and revascularization (30.4% vs 26.7%, p = 0.43). After adjusting for baseline variables, abciximab did not influence the occurrence of late adverse events.


Subject(s)
Angioplasty, Balloon, Coronary/adverse effects , Antibodies, Monoclonal/therapeutic use , Coronary Disease/complications , Coronary Disease/therapy , Diabetes Complications , Immunoglobulin Fab Fragments/therapeutic use , Platelet Aggregation Inhibitors/therapeutic use , Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors , Stents/adverse effects , Abciximab , Aged , Angioplasty, Balloon, Coronary/mortality , Combined Modality Therapy , Coronary Angiography , Coronary Disease/classification , Coronary Disease/diagnostic imaging , Female , Humans , Male , Middle Aged , Myocardial Infarction/etiology , Proportional Hazards Models , Recurrence , Retrospective Studies , Risk Factors , Severity of Illness Index , Survival Analysis , Time Factors , Treatment Outcome
6.
Catheter Cardiovasc Interv ; 51(2): 138-44, 2000 Oct.
Article in English | MEDLINE | ID: mdl-11025564

ABSTRACT

Abciximab is effective for the prevention of complications when administered prior to percutaneous coronary intervention (PCI). The efficacy and safety of abciximab as an unplanned or rescue agent for complications of PCI is unknown. Rescue versus planned use was compared in 186 consecutive patients. Primary or rescue PCI for acute myocardial infarction (MI) and shock were excluded. Rescue abciximab use was undertaken in 101 patients (54.3%) and planned abciximab was used in 85 (45.7%). The rescue abciximab patients had a lower incidence of previous MI, preprocedural thrombus, multivessel, and vein graft intervention. In-hospital endpoints in the rescue versus planned abciximab patients were death (1.0% vs. 1. 2%, P = 1.0), Q-wave MI (2.0% vs. 2.4%, P = 1.0), any MI (14.9% vs. 9.4%, P = 0.3), target vessel revascularization (TVR; 0% vs. 1.2%, P = 1.0), and composite (15.8% vs. 10.6%, P = 0.3). At 6 months, events were death (4.0% vs. 2.3%, P = 0.69), MI (14.9% vs. 9.4%, P = 0.26), TVR (20.8% vs. 4.7%, P = 0.001), and composite (30.7% vs. 15. 3%, P = 0.01). In-hospital complications between the rescue and planned abciximab patients of major bleed (1.0% vs. 1.8%, P = NS), stroke (0% vs. 1.8%, P = NS), and thrombocytopenia (3.0% vs. 1.8%, P = NS) were similar. There was a significantly higher procedural time (99.6 min vs. 86.1 min, P = 0.02), contrast volume (278.8 ml vs. 223. 5 ml, P = 0.04), and heparin use (8984 u vs. 6003 u, P = 0.0006) in the rescue group. In this nonrandomized comparison, rescue abciximab allowed for the safe discharge from hospital in the majority of patients. However, during a 6-month follow-up, more patients treated with rescue abciximab required TVR with either repeat PCI or CABG. Further studies are warranted to evaluate the overall strategy of rescue abciximab use in PCI.


Subject(s)
Angioplasty, Balloon, Coronary , Antibodies, Monoclonal/therapeutic use , Coronary Disease/therapy , Immunoglobulin Fab Fragments/therapeutic use , Platelet Aggregation Inhibitors/therapeutic use , Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors , Abciximab , Aged , Antibodies, Monoclonal/administration & dosage , Coronary Angiography , Female , Humans , Immunoglobulin Fab Fragments/administration & dosage , Male , Middle Aged , Platelet Aggregation Inhibitors/administration & dosage , Treatment Outcome
7.
Mayo Clin Proc ; 75(10): 994-1001, 2000 Oct.
Article in English | MEDLINE | ID: mdl-11040846

ABSTRACT

OBJECTIVE: To characterize and determine the overall impact of changes in primary percutaneous coronary intervention (PCI) on the clinical outcome of patients presenting within 24 hours of acute myocardial infarction (AMI). PATIENTS AND METHODS: We retrospectively analyzed a prospective PCI registry for 1073 consecutive patients undergoing primary PCI for AMI at the Mayo Clinic in Rochester, Minn, from 1991 through 1997. The primary outcome measure was mortality from any cause within 30 days and 1 year. RESULTS: The number of patients treated for AMI by primary PCI per year increased from 119 in 1991 to 193 in 1997. Intracoronary stent use increased from 1.7% in 1991 to 64.8% in 1997 (P < .001). This coincided with an increase in ticlopidine use from 3.6% in 1994 to 62.1% in 1997 (P < .001) and in abciximab use from 2.7% in 1995 to 63.2% in 1997 (P < .001). An increase in beta-blocker (58.3% to 75.3%; P < .001), angiotensin-converting enzyme inhibitor (0.9% to 40.0%; P < .001), and 3-hydroxy-3-methylglutaryl coenzyme A reductase use (1.9% to 40.5%; P < .001) as well as a decrease in calcium channel antagonist (34.3% to 8.4%; P < .001) use occurred on discharge. From 1991 through 1997, there was a significant decrease in the 30-day mortality rate (10.1% to 5.2%; P = .05). The 1-year mortality rate also decreased (13.4% in 1991 to 10.4% in 1997) (P = .09). After adjustment for other confounding variables, treatment in more recent years was associated with a significant decrease in death at 30 days (odds ratio, 0.89; 95% confidence interval, 0.79-1.00; P = .05) and during long-term follow-up (odds ratio, 0.93; 95% confidence interval, 0.87-1.00; P = .04). CONCLUSIONS: Percutaneous coronary intervention methods of reperfusion for AMI, along with adjuvant pharmacotherapy, have changed over recent years and have been associated with improved short- and long-term survival.


Subject(s)
Angioplasty, Balloon, Coronary , Myocardial Infarction/therapy , Abciximab , Adrenergic beta-Antagonists/therapeutic use , Aged , Angioplasty, Balloon, Coronary/statistics & numerical data , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Antibodies, Monoclonal/therapeutic use , Calcium Channel Blockers/therapeutic use , Cause of Death , Confidence Intervals , Confounding Factors, Epidemiologic , Female , Follow-Up Studies , Hospitals, Group Practice , Humans , Hydroxymethylglutaryl CoA Reductases/therapeutic use , Immunoglobulin Fab Fragments/therapeutic use , Male , Middle Aged , Minnesota/epidemiology , Myocardial Infarction/drug therapy , Myocardial Infarction/mortality , Odds Ratio , Platelet Aggregation Inhibitors/therapeutic use , Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors , Retrospective Studies , Stents/statistics & numerical data , Survival Rate , Ticlopidine/therapeutic use , Treatment Outcome
8.
Ann Intern Med ; 131(11): 838-41, 1999 Dec 07.
Article in English | MEDLINE | ID: mdl-10610629

ABSTRACT

BACKGROUND: Manifestations of cardiac amyloidosis may include congestive heart failure and sudden cardiac death. Although vascular involvement in patients with amyloidosis is common, systemic amyloidosis presenting with angina is rare. OBJECTIVES: To report on patients with systemic amyloidosis presenting with angina pectoris. DESIGN: Case series. SETTING: Academic medical center. PATIENTS: Five patients who presented with angina pectoris and normal coronary angiogram as the initial manifestation of systemic amyloidosis. MEASUREMENTS: Endothelial-dependent and endothelial-independent coronary flow reserve. RESULTS: All patients had coronary flow reserve abnormalities and subsequently developed congestive heart failure and systemic manifestations of amyloidosis. Histologic evaluation revealed amyloid deposition in the intramyocardial coronary vessels. CONCLUSIONS: Cardiac amyloidosis can present as angina pectoris associated with coronary flow reserve abnormalities despite normal coronary angiograms. This finding may have major therapeutic and prognostic implications in this patient population.


Subject(s)
Amyloidosis/complications , Angina Pectoris/etiology , Aged , Amyloidosis/pathology , Angina Pectoris/diagnostic imaging , Angina Pectoris/physiopathology , Coronary Angiography , Coronary Circulation , Coronary Disease/etiology , Coronary Disease/pathology , Female , Follow-Up Studies , Humans , Male , Middle Aged
9.
Am J Cardiol ; 83(7): 1006-11, 1999 Apr 01.
Article in English | MEDLINE | ID: mdl-10190510

ABSTRACT

In patients receiving coronary stents treated with aspirin and coumadin, the peak incidence of stent thrombosis occurs on the fifth and sixth days following the implantation procedure. Little is known about the timing of stent thrombosis in patients treated with aspirin and ticlopidine. We compared the timing of coronary stent thrombosis in patients treated with ticlopidine and aspirin with the timing in those receiving coumadin and aspirin. A retrospective databank analysis was performed and 39 patients were identified who experienced stent thrombosis after successful coronary stent implantation. Of these, 21 had been treated with ticlopidine and aspirin and 18 with coumadin and aspirin therapy. The median time from stent implantation to stent thrombosis in the ticlopidine and aspirin group was 12 hours (interquartile range 6 to 72 hours) compared with 4 days in the coumadin and aspirin group (interquartile range 21 to 68 hours) (p <0.0001). There was no significant difference between the timing of stent thrombosis in patients treated with abciximab in addition to ticlopidine and aspirin (median 17 hours, interquartile range 6 to 29) versus ticlopidine and aspirin patients who did not receive abciximab (median 11 hours, interquartile range 9 to 12, p = 0.57). Thus, in patients who receive coronary stents, stent thrombosis occurs much earlier after the procedure in patients treated with ticlopidine and aspirin than in patients treated with anticoagulation therapy.


Subject(s)
Aspirin/administration & dosage , Coronary Vessels , Platelet Aggregation Inhibitors/administration & dosage , Stents , Thrombosis/prevention & control , Ticlopidine/administration & dosage , Angioplasty, Balloon, Coronary , Anticoagulants/administration & dosage , Coronary Angiography , Coronary Disease/therapy , Drug Therapy, Combination , Female , Humans , Male , Middle Aged , Retrospective Studies , Stents/adverse effects , Thrombosis/diagnostic imaging , Thrombosis/etiology , Time Factors , Warfarin/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...